SCHEMBL12481107

SCHEMBL12481107

Fc1ccc2c(c1)nc(Cl)c1ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.42
MAPK1 P28482 3/20 0.41
CYP3A4 P08684 2/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
APEX1 P27695 1/20 0.41
PMP22 Q01453 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
CYP1A2 P05177 2/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
CYP2C9 P11712 1/20 0.40
CASP1 P29466 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 1/20 0.40
MAPK10 P53779 1/20 0.40
CASP7 P55210 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR4 Q13639 1/20 0.39
RXFP1 Q9HBX9 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12481032 0.87 MAOA (0.44) ACHETDP1NPC1TP53RAB9A
SCHEMBL856384 0.78 MPO (0.43) ACHEMAPTTDP1RXFP1KDM4E
SCHEMBL17752895 0.78 PTGES (0.41) ACHEMAPK1CYP3A4MAPTLMNA
SCHEMBL12480194 0.78 KDM4E (0.43) ACHEMAPK1CYP3A4MAPTCYP1A2
SCHEMBL16905530 0.78 ACHE (0.49) ACHEMAPK1CYP3A4MAPTCYP1A2
SCHEMBL29490199 0.78 MPO (0.43) ACHEMAPTTDP1RXFP1KDM4E
SCHEMBL516091 0.78 TDP1 (0.59) ACHEMAPK1CYP3A4MAPTLMNA
SCHEMBL30014038 0.77 ACHE (0.42) ACHEMAPK1MAPTSMN1; SMN2KDM4E
SCHEMBL1994310 0.77 ACHE (0.42) ACHEMAPK1MAPTSMN1; SMN2KDM4E
SCHEMBL6404610 0.75 KMT2A (0.44) ACHEMAPK1CYP3A4MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8951964-B2 Phenanthridine macrocyclic hepatitis C serine protease inhibitors ABBVIE INC. (US) 2015-02-10 US disclosed
US-8951964-B2 Phenanthridine macrocyclic hepatitis C serine protease inhibitors ABBVIE INC. (US) 2015-02-10 US disclosed
US-8951964-B2 Phenanthridine macrocyclic hepatitis C serine protease inhibitors ABBVIE INC. (US) 2015-02-10 US disclosed
EP-2658858-A2 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2013-11-06 EP disclosed
US-20120295842-A1 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBVIE INC. 2012-11-22 US disclosed
US-20120295842-A1 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBVIE INC. 2012-11-22 US disclosed
US-20120295842-A1 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBVIE INC. 2012-11-22 US disclosed
WO-2012092411-A2 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2012-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295842-A1 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS TMPRSS15, HPN, PRSS1 ACHE 1035/4885MAPK1 3656/4885CYP3A4 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.